These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22941306)

  • 1. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
    Dagorne A; Douet-Guilbert N; Quintin-Roue I; Guillerm G; Couturier MA; Berthou C; Ianotto JC
    Ann Hematol; 2013 Mar; 92(3):407-9. PubMed ID: 22941306
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis.
    Berneman ZN; Anguille S; Van Marck V; Schroyens WA; Van Tendeloo VF
    Br J Haematol; 2010 Apr; 149(1):152-5. PubMed ID: 19995392
    [No Abstract]   [Full Text] [Related]  

  • 3. [Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis].
    Remes K; Pelliniemi TT
    Duodecim; 1993; 109(11):983-9. PubMed ID: 8062671
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel prognosis of acute myeloid leukemia: AML-M2 complicate with thrombocythemia after complete remission.
    Chen YX; Li Y; Zhang LY; Liu B
    Leuk Res; 2012 Aug; 36(8):e166-7. PubMed ID: 22579367
    [No Abstract]   [Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.
    Alchalby H; Zabelina T; Stübig T; van Biezen A; Bornhäuser M; Di Bartolomeo P; Beelen D; Cahn JY; Dreger P; Schroyens W; de Witte T; Olavarria E; Kröger N;
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):279-81. PubMed ID: 24201159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
    Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.
    Hebballi S; Akiki S; Bareford D
    J Clin Pathol; 2012 Aug; 65(8):762-3. PubMed ID: 22412053
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
    Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ
    Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of essential thrombocythemia evolving into agnogenic myeloid metaplasia with interferon-alpha.
    Kikawa Y; Fukumoto Y; Obata K; Tamura S; Takeuchi M; Tanizawa A; Mayumi M
    J Pediatr Hematol Oncol; 1998; 20(5):463-6. PubMed ID: 9787320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
    Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
    J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia.
    Marvin KS; Spellberg RD
    Chest; 1993 Feb; 103(2):642-4. PubMed ID: 8432180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation and management of patients presenting with thrombocytosis].
    Cheminant M; Delarue R
    Rev Med Interne; 2013 Aug; 34(8):465-71. PubMed ID: 23498669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon].
    Gotić M; Cvetković M; Bozanović T; Cemerikić V
    Srp Arh Celok Lek; 2001; 129(11-12):304-8. PubMed ID: 11928616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous resolution of myelofibrosis and pancytopenia followed by the development of acute myeloid leukemia with an extramedullary mass.
    Inoue S; Limsuwan A; McQueen R
    J Pediatr Hematol Oncol; 1998; 20(3):268-70. PubMed ID: 9628442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eleven-year follow-up of "primary thrombocythemia" in a child.
    Amato D; Freedman MH
    J Pediatr; 1984 Apr; 104(4):639. PubMed ID: 6707827
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
    Jootar S
    Asian Pac J Allergy Immunol; 1989 Dec; 7(2):103-5. PubMed ID: 2624663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
    Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
    Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocytosis: diagnostic and treatment dilemmas.
    Dugan V; Higginbotham R; Gilbert J; Lipscomb G; Lopez FA
    J La State Med Soc; 2003; 155(6):306-13. PubMed ID: 14750750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.